Ranbaxy Hit With Class Action Over Generic Lipitor Recall

Law360, New York (December 4, 2012, 3:21 PM EST) -- Ranbaxy Inc. was hit with a putative class action filed in New Jersey federal court last week, alleging the company’s recall of its generic version of blockbuster cholesterol treatment Lipitor did not warn or compensate consumers adequately of the drug.

Ranbaxy, the American arm of India-based drugmaker Ranbaxy Laboratories Ltd., began recalling 41 lots of generic Lipitor, or atorvastatin, from retailers Nov. 9, because of concerns the pills might contain tiny glass fragments, comparable to fine grains of sand less than one millimeter in size, according...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

FENWICK v. RANBAXY PHARMACEUTICALS, INC. et al


Case Number

3:12-cv-07354

Court

New Jersey

Nature of Suit

Other Statutory Actions

Judge

Peter G. Sheridan

Date Filed

November 29, 2012

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.